Potential shift from coronary bypass surgery to percutaneous coronary intervention for multivessel disease and its economic impact in the drug-eluting stent era

Canadian Journal of Cardiology

Volumn 23, Issue 14, 2007, Pages 1139-1145

  Poulin, Frédéric ^a   Rinfret, Stéphane ^a   Gobeil, François ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Coronary artery bypass grafting surgery; Drug eluting stents; Economic analysis; Multivessel disease; Percutaneous coronary intervention

Indexed keywords

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; TREATMENT INDICATION; ANGIOCARDIOGRAPHY; BLOOD VESSEL TRANSPLANTATION; CANADA; COST; ECONOMICS; FOLLOW UP; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; RETROSPECTIVE STUDY; STATISTICS; STENT; TREATMENT OUTCOME;

BIOMATERIAL;

AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; COSTS AND COST ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUEBEC; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 38549090116     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70885-1     Document Type: Article

References (35)

1. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-81.
2. Rodriguez AE, Baldi J, Fernández Pereira C, et al; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005;46:582-8.
3. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stenr implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): A randomised controlled trial. Lancer 2002;360:965-70.
4. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-83.
5. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
6. Hill RA, Dündar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: An early systematic review to inform policy. Eur Heart J 2004;25:902-19.
7. Serruys PW, Ong AT, Morice M-C, et al. Arterial Revascularization Therapies Study Part II - sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 2005;1:147-56.
8. Rodriguez AE, Grinfeld L, Fernandez-Pereira C, et al. Revascularization strategies of coronary multiple vessel disease in the drug eluting stent era: One year follow-up results of the ERACI III Trial. Eurointervention 2006;2:53-60.
9. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
10. Camenzind E, Steg PG, Wijns W. [Hotline session I]. A meta-analysis of first generation drug eluting stent programs. World Congress of Cardiology 2006. Barcelona, September 2 to 5, 2006. (Abst)
11. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
12. Kaiser C, Brunner-La Rocca HP, Buser PT, et al; BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9. (Erratum in 2005;366:2086).
13. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
14. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:217-25. (Erratum in 1997;336:147).
15. Calif RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
16. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114-30.
17. Smith SC Jr, Dove JT, Jacobs AK, et al; American College of Cardiology/ American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty); Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-41.
18. Brophy JE, et al. An economic analysis of drug eluting coronary stents: A Quebec perspective. In: des AdEdTe, (AETMIS) MdIeS, eds. AETMIS. Quebec, 2004.
19. Shrive FM, Manns BJ, Galbraith PD, Knudtson ML, Ghali WA; APPROACH Investigators. Economic evaluation of sirolimuseluting stents. CMAJ 2005;172:345-51.
20. Griffiths H, Bakhai A, West D, et al. Feasibility and cost of treatment with drug eluting stents of surgical candidates with multivessel coronary disease. Eur J Cardiothorac Surg 2004;26:528-34.
21. Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: Pooled analysis of five clinical trials. J Am Coll Cardiol 2006;48:21-31.
22. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
23. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006;113:2803-9.
24. Cohen DJ, Bakhai A, Shi C, et al; SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-14.
25. Rinfret S, Cohen DJ, Tahami Monfared AA, Lelorier J, Mireault J, Schampaert F. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: An analysis from the C-SIRIUS trial. Am J Cardiovasc Drugs 2006;6:159-68.
26. van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart 2005;91:507-12.
27. Bourassa MG, Yeh W, Holubkov R, Sopko C, Detre KM. Long-term outcome of patients with incomplete vs complete revascularization after multivessel PTCA. A report from the NHLBI PTCA Registry. Eur Heart J 1998;19:103-11.
28. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006;113:2406-12.
29. Mariani G, De Servi S, Dellavalle A, et al; ROSAI Study Group. Complete or incomplete percutaneous coronary revascularization in patients with unstable angina in stent era: Are early and one-year results different? Catheter Cardiovasc Interv 2001;54:448-53.
30. Nikolsky F, Gruberg L, Patil CV, et al. Percutaneous coronary interventions in diabetic patients: Is complete revascularization important? J Invasive Cardiol 2004;16:102-6.
31. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002;39:559-64.
32. McLellan CS, Ghali WA, Labinaz M, et al; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005;150:800-6.
33. Danchin N, Juillière Y, Foley D, Serruys PW. Visual versus quantitative assessment of the severity of coronary artery stenoses: Can the angiographer's eye be reeducated? Am Heart J 1993;126:594-600.
34. Kussmaul WG III, Popp RL, Norcini J. Accuracy and reproducibility of visual coronary stenosis estimates using information from multiple observers. Clin Cardiol 1992;15:154-62.
35. Gottsauner-Wolf M, Sochor H, Moertl D, Gwechenberger M, Stockenhuber F, Probst P. Assessing coronary stenosis. Quantitative coronary angiography versus visual estimation from cine-film or pharmacological stress perfusion images. Eur Heart J 1996;17:1167-74.